Pharmaceutical Grade Lactose Market Overview
The
pharmaceutical grade lactose market size was valued at USD 0.2 Billion in 2023.
The pharmaceutical grade lactose industry is projected to grow from USD 0.21
Billion in 2023 to USD 0.29 Billion by 2032, exhibiting a compound annual
growth rate (CAGR) of 4.40% during the forecast period (2023 - 2032).
Pharmaceutical
grade lactose has been used as an excipient for more than a century. Because of
its versatility, it is the backbone of many successful formulations. It is
produced by concentrating whey or permeate (a co-product of whey protein
concentrates production) to over-saturate the lactose, then removing, refining,
drying, and milling the lactose crystals. Pharmaceutical grade lactose market is produced to meet rigid specifications, such as
specific form and size distribution, monohydrate, crystalline, 40 mesh to 325
mesh, and a spray-dried mixture of crystalline and amorphous lactose for all
applications.
Key
Players
The
Global Pharmaceutical Grade Lactose Market players are Kerry Inc. (Ireland),
DFE Pharma (Germany), Meggle Excipients & Technology (Germany), Merck KGaA
(Germany), Armor Pharma (France), ALPAVIT (Germany), BASF SE (Germany)
Segment
Analysis
The
global pharmaceutical grade lactose market report has been segmented based on type, and application.
The market, based on type, has been segmented into Crystalline Monohydrate
Lactose, Inhalation Lactose, Granulated Lactose, Spray Dried Lactose, and
others. Crystalline Monohydrate Lactose is further segmented into α-Lactose
monohydrate, and β-Lactose (anhydrous lactose). Inhalation Lactose is further
segmented into Sieved and Milled.
The
global pharmaceutical grade lactose market, by application, has been
categorized as tablets manufacturing, capsule manufacturing, and others.
Tablets manufacturing is further segmented into direct compression, wet
granulation, and dry granulation. Capsule manufacturing is further segmented
into capsules, sachets, and others.
Regional
Analysis
Europe
was the largest market for pharmaceutical grade lactose in 2019. Europe is
anticipated to witness significant growth over the forecast period owing to the
presence of a higher number of manufacturers and manufacturing associations in
the region. For instance, key players headquartered in Europe include BASF
Corporation, Merck KGaA, Kerry Inc., DFE Pharma, and others. The association of
excipient manufacturers setting stringent norms and good manufacturing
practices (GMP) are reasons for standardization of the manufacturing process.
The norms and GMPs set forth by the International Pharmaceutical Excipients
Council, Europe brings producers, distributors, and users of pharmaceutical
excipients together in one place to share experiences and knowledge to learn
and to lead the future of excipients. The IPEC Federation represents the five
existing regional International Pharmaceutical Excipient Councils (IPECs) -
IPEC-Americas, IPEC Europe, IPEC Japan, IPEC China, and IPEC India. EXCiPACT is a not-for-profit organization that
develops and manages a high-quality certification scheme for producers,
suppliers, and distributors of pharmaceutical excipients.
Asia-Pacific
is the second-largest market for pharmaceutical grade lactose. According to the
United Nations, across Asia, the number of people aged 65 and above is expected
to grow dramatically over the next 50 years. For the region, the population in
this age group will increase by 314% from 207 million in 2000 to 857 million in
2050. Research conducted by the World Bank estimated that the number of
projected cases of COPD in China would be 42.5 million in 2020 and 55.2 million
in 2032. According to research published in The Lancet, the number of cases of
COPD in India increased from 28.1 million in 1990 to 55.3 million in 2016, an
increase in prevalence from 3.3% to 4.2%.
Americas
is the third-largest market for pharmaceutical grade lactose. This share is
owing to the high prevalence of the population suffering from chronic
obstructive pulmonary diseases (COPD). During 2018, approximately 9 million
adults were diagnosed with chronic bronchitis in the US. COPD was the fourth leading
cause of death in the US. According to the Canters for Disease Control and
Prevention (CDC), more than 25 million Americans have asthma. The annual per-person incremental medical cost of
asthma was USD 3,266 in 2015.
The market for pharmaceutical grade lactose is growing in the Middle
East and Africa due to various reasons such as the high prevalence of COPD and the presence of
distributors and subsidiaries in the region. DFE Pharma has its distributors
located in Morocco, Algeria, South Africa, Egypt, Iran, and other countries in
the Middle East. The BASF Group has been active on the African continent for
close to 90 years. BASF employs around 1600 people in Africa. Since 2016, the
BASF African headquarters is based in Nairobi, Kenya. Armor Pharma has its
local partners situated in the region in nearly 20 countries.
Other
trending Reports-
No comments:
Post a Comment